The University of Chicago Header Logo

Connection

Sandeep Gurbuxani to Humans

This is a "connection" page, showing publications Sandeep Gurbuxani has written about Humans.
Connection Strength

0.652
  1. SETBP1 sets the stage. Blood. 2024 04 04; 143(14):1323-1324.
    View in: PubMed
    Score: 0.031
  2. The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
    View in: PubMed
    Score: 0.029
  3. EBV-positive inflammatory FDC/FRC tumor: no longer pseudo or sarcoma! Blood. 2023 02 23; 141(8):961.
    View in: PubMed
    Score: 0.029
  4. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.
    View in: PubMed
    Score: 0.027
  5. bcr3 PML-RARA: short fusion, small blasts! Blood. 2021 05 13; 137(19):2708.
    View in: PubMed
    Score: 0.025
  6. CXCL4's "Gliful" subversion of BM in MPN. Blood. 2020 10 29; 136(18):1999-2000.
    View in: PubMed
    Score: 0.024
  7. Red cell morphology in sickle cell disease. Blood. 2020 10 15; 136(16):1893.
    View in: PubMed
    Score: 0.024
  8. Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders. Leuk Lymphoma. 2019 12; 60(12):2847-2848.
    View in: PubMed
    Score: 0.023
  9. The web of microRNA in B lymphoblastic leukemia. Leuk Lymphoma. 2017 09; 58(9):2024-2025.
    View in: PubMed
    Score: 0.020
  10. PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-a rearrangement. Blood. 2014 Apr 24; 123(17):2742-3.
    View in: PubMed
    Score: 0.015
  11. Cloaked in a starry sky. Blood. 2014 Apr 10; 123(15):2291.
    View in: PubMed
    Score: 0.015
  12. On a WHIM. Blood. 2013 Feb 07; 121(6):875.
    View in: PubMed
    Score: 0.014
  13. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. Semin Diagn Pathol. 2012 Feb; 29(1):2-11.
    View in: PubMed
    Score: 0.013
  14. Diffuse large B-cell lymphoma--more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch Pathol Lab Med. 2009 Jul; 133(7):1121-34.
    View in: PubMed
    Score: 0.011
  15. Resident training in laboratory hematology. Clin Lab Med. 2007 Jun; 27(2):359-68; abstract vii-viii.
    View in: PubMed
    Score: 0.010
  16. What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective. Clin Gastroenterol Hepatol. 2007 Apr; 5(4):417-21.
    View in: PubMed
    Score: 0.009
  17. WT1 expression in myelodysplastic syndrome. Leuk Lymphoma. 2007 Mar; 48(3):456-7.
    View in: PubMed
    Score: 0.009
  18. CD36 - a marker for drug sensitive acute megakaryoblastic leukemia. Leuk Lymphoma. 2006 Oct; 47(10):2004-5.
    View in: PubMed
    Score: 0.009
  19. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A. 2005 Aug 09; 102(32):11480-5.
    View in: PubMed
    Score: 0.008
  20. PHF6 suppresses self-renewal of leukemic stem cells in AML. Leukemia. 2024 Sep; 38(9):1938-1948.
    View in: PubMed
    Score: 0.008
  21. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.008
  22. Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
    View in: PubMed
    Score: 0.008
  23. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.008
  24. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.008
  25. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.008
  26. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004 Jan 15; 103(2):399-406.
    View in: PubMed
    Score: 0.007
  27. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.007
  28. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.007
  29. Gut commensal bacteria enhance pathogenesis of a tumorigenic murine retrovirus. Cell Rep. 2022 09 13; 40(11):111341.
    View in: PubMed
    Score: 0.007
  30. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.007
  31. GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. Am J Clin Pathol. 2022 08 04; 158(2):228-234.
    View in: PubMed
    Score: 0.007
  32. Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022 07 06; 3(4):298-315.
    View in: PubMed
    Score: 0.007
  33. B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. Hum Pathol. 2022 07; 125:48-58.
    View in: PubMed
    Score: 0.007
  34. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
    View in: PubMed
    Score: 0.007
  35. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022 02; 61(2):71-80.
    View in: PubMed
    Score: 0.007
  36. Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients. Cancer Lett. 2001 Jun 10; 167(1):73-83.
    View in: PubMed
    Score: 0.006
  37. A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. J Pathol Clin Res. 2021 09; 7(5):459-470.
    View in: PubMed
    Score: 0.006
  38. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
    View in: PubMed
    Score: 0.006
  39. MDR1 mRNA expression in young patients with acute lymphoblastic leukaemia. Br J Haematol. 2000 Jun; 109(4):897-9.
    View in: PubMed
    Score: 0.006
  40. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.006
  41. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin Cancer Res. 2019 09 15; 25(18):5638-5649.
    View in: PubMed
    Score: 0.006
  42. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019 Aug 15; 25(16):4898-4906.
    View in: PubMed
    Score: 0.005
  43. Head and Neck Sinus Histiocytosis with Massive Lymphadenopathy Radiology-Pathology Correlation. Head Neck Pathol. 2019 Dec; 13(4):656-660.
    View in: PubMed
    Score: 0.005
  44. Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. Ann Hematol. 1998 May; 76(5):195-200.
    View in: PubMed
    Score: 0.005
  45. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697.
    View in: PubMed
    Score: 0.005
  46. Detection of BCR-ABL transcripts in acute lymphoblastic leukemia in Indian patients. Leuk Res. 1998 Jan; 22(1):77-80.
    View in: PubMed
    Score: 0.005
  47. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459.
    View in: PubMed
    Score: 0.005
  48. A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Head Neck Pathol. 2018 Jun; 12(2):286-290.
    View in: PubMed
    Score: 0.005
  49. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest. 2017 Apr 03; 127(4):1316-1320.
    View in: PubMed
    Score: 0.005
  50. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. Cancer Cell. 2017 01 09; 31(1):127-141.
    View in: PubMed
    Score: 0.005
  51. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.
    View in: PubMed
    Score: 0.005
  52. Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis. PLoS One. 2016; 11(9):e0162515.
    View in: PubMed
    Score: 0.005
  53. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol. 2016 10; 29(10):1173-82.
    View in: PubMed
    Score: 0.004
  54. Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80.
    View in: PubMed
    Score: 0.004
  55. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452.
    View in: PubMed
    Score: 0.004
  56. Identification of MLL-fusion/MYC?miR-26?TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 2016 Mar 28; 372(2):157-65.
    View in: PubMed
    Score: 0.004
  57. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease. Cancer Res. 2016 Feb 01; 76(3):619-29.
    View in: PubMed
    Score: 0.004
  58. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15.
    View in: PubMed
    Score: 0.004
  59. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7.
    View in: PubMed
    Score: 0.004
  60. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
    View in: PubMed
    Score: 0.004
  61. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11994-9.
    View in: PubMed
    Score: 0.004
  62. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11511-6.
    View in: PubMed
    Score: 0.004
  63. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.004
  64. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90.
    View in: PubMed
    Score: 0.004
  65. Stem cell factor expression in B cell malignancies is influenced by the niche. Leuk Lymphoma. 2013 Oct; 54(10):2274-80.
    View in: PubMed
    Score: 0.004
  66. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19397-402.
    View in: PubMed
    Score: 0.003
  67. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35.
    View in: PubMed
    Score: 0.003
  68. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.003
  69. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012 Mar; 122(3):948-62.
    View in: PubMed
    Score: 0.003
  70. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.003
  71. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010 Nov; 24(11):1920-6.
    View in: PubMed
    Score: 0.003
  72. Intracranial mucosa-associated lymphoid tissue (MALT) lymphoma. J Clin Neurosci. 2010 May; 17(5):666-9.
    View in: PubMed
    Score: 0.003
  73. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine. 2008 Oct; 9(4):374-6.
    View in: PubMed
    Score: 0.003
  74. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008 Jan 15; 111(2):767-75.
    View in: PubMed
    Score: 0.002
  75. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):19-23.
    View in: PubMed
    Score: 0.002
  76. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):59-62.
    View in: PubMed
    Score: 0.002
  77. Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res. 2004 Apr 15; 64(8):2705-11.
    View in: PubMed
    Score: 0.002
  78. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6.
    View in: PubMed
    Score: 0.002
  79. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol. 2003 Aug; 23(16):5790-802.
    View in: PubMed
    Score: 0.002
  80. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003 Jun 01; 101(11):4298-300.
    View in: PubMed
    Score: 0.002
  81. Incidence, clinical characteristics and early treatment outcome in Indian patients of childhood acute lymphoblastic leukemia with ALL-1 gene rearrangement. Leuk Res. 2001 Aug; 25(8):693-8.
    View in: PubMed
    Score: 0.002
  82. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000 Sep; 2(9):645-52.
    View in: PubMed
    Score: 0.002
  83. Pattern of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in childhood acute lymphoblastic leukemia in India. Leuk Res. 2000 Jul; 24(7):575-82.
    View in: PubMed
    Score: 0.001
  84. A prospective study on the incidence of hepatitis B & C infections amongst patients with lymphoproliferative disorders. Indian J Med Res. 1998 Feb; 107:78-82.
    View in: PubMed
    Score: 0.001
  85. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol. 1996 Jul; 94(1):23-33.
    View in: PubMed
    Score: 0.001
  86. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer. 1996 Jun; 32A(6):1034-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.